The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells
2007

Bortezomib Sensitivity in Lung Cancer Cells

publication Evidence: moderate

Author Information

Author(s): Voortman Jens, Chęcińska Agnieszka, Giaccone Giuseppe

Primary Institution: VU University Medical Center

Hypothesis

The sensitivity of non-small cell lung cancer (NSCLC) cells to bortezomib is determined by their proteasomal and apoptotic phenotypes.

Conclusion

Successful treatment strategies using proteasome inhibitors in NSCLC must address both apoptosis resistance and proteasomal resistance in individual cancer cells.

Supporting Evidence

  • NSCLC cell lines showed different sensitivity to bortezomib, with IC50 values ranging from 5 to 83 nM.
  • H460 cells were more susceptible to apoptosis induction by bortezomib than SW1573 cells.
  • Overexpression of Bcl-2 in H460 cells decreased bortezomib-induced apoptosis.

Takeaway

Some lung cancer cells respond to a drug called bortezomib, but others don't because of differences in how they handle proteins and how they die.

Methodology

The study used MTT assays to determine growth inhibition and flow cytometry for apoptosis analysis in NSCLC cell lines treated with bortezomib.

Limitations

The study primarily focused on cell lines, which may not fully represent the complexity of tumor responses in patients.

Digital Object Identifier (DOI)

10.1186/1476-4598-6-73

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication